Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price dropped 4.3% during mid-day trading on Wednesday . The company traded as low as $8.60 and last traded at $8.60, with a volume of 81,063 shares changing hands. The stock had previously closed at $8.99.

COLL has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Piper Jaffray Cos. restated an “overweight” rating and issued a $26.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up previously from $28.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus price target of $28.25.

The stock has a 50 day moving average price of $11.60 and a 200 day moving average price of $15.44. The stock’s market capitalization is $195.99 million.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. On average, equities analysts expect that Collegium Pharmaceutical Inc. will post ($3.88) earnings per share for the current fiscal year.

In related news, Director John A. Fallon acquired 2,375 shares of the firm’s stock in a transaction dated Friday, August 12th. The stock was acquired at an average price of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now directly owns 2,375 shares in the company, valued at approximately $25,151.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.